<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462160</url>
  </required_header>
  <id_info>
    <org_study_id>UTI probiotic</org_study_id>
    <nct_id>NCT03462160</nct_id>
  </id_info>
  <brief_title>Effectiveness of Probiotics Prophylaxis of Urinary Tract Infections in Children</brief_title>
  <official_title>Effectiveness of Prophylaxis of Urinary Tract Infections in Children With a Probiotic Containing Lactobacillus Rhamnosus PL1 and Lactobacillus Plantarum PM1, a Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Miralex Sp. z o.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to assess the effectiveness of prophylaxis of urinary tract infections
      in children with a probiotic containing Lactobacillus rhamnosus PL1 and Lactobacillus
      plantarum PM1. It is formulated a hypothesis that a 3-months course of probiotic prophylasis
      is more effective than placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In previously published European and global guidelines, there has been no consensus among
      experts regarding the prophylaxis of recurrence urinary tract infections. Depending on the
      recommendation, the prevention of recurrence UTI should be used, not justified, or should be
      used in special cases. However, preparations that will be effective in preventing UTI and
      will not cause bacterial resistance are still sought.

      106 patients aged 3 to 18 years with recurrence UTIs (defined as: ≥2 infections in the upper
      urinary tract or 1 UTI in the upper urinary tract and ≥1 in the lower urinary tract or ≥3 or
      more UTI in the lower urinary tract in one year) or children with ≥1 infection in the upper
      urinary tract and ≥1 of recurrent UTIs risk factors (congenital anomalies of the kidney and
      urinary tract, constipation, bladder dysfunction, myelomeningocele, sexual activity in girls)
      will be randomly assigned to receive a 90-days prophylaxsis arm (probiotic UroLact containing
      Lactobacillus Rhamnosus PL1 and Lactobacillus Plantarum PM1) or a 90-days placebo arms.

      The primary outcome measure will be frequencies of recurrence of UTI during the 6 months
      after the intervention.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequencies of recurrence of UTI</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>New onset of symptomatic UTI within the 6 months follow-up period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequencies of hospitalization due to UTI</measure>
    <time_frame>6 months after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of days of antibiotic therapy due to UTI</measure>
    <time_frame>6 months after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Prevention of Urinary Tract Infections in Children</condition>
  <arm_group>
    <arm_group_label>Placebo supply for 90 days</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo (in blinded sachets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic supply for 90 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 (in blinded sachets).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo control group</intervention_name>
    <description>Placebo will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal. The placebo appearance will be similar to the probiotic.</description>
    <arm_group_label>Placebo supply for 90 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic experimental group</intervention_name>
    <description>Probiotic UroLact containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal.</description>
    <arm_group_label>Probiotic supply for 90 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  recurrent UTIs (defined as: ≥2 infections in the upper urinary tract or 1 UTI in the
             upper urinary tract and ≥1 in the lower urinary tract or ≥3 or more UTI in the lower
             urinary tract in one year) OR 1 infection in the upper urinary tract and ≥1 of
             recurrent UTIs risk factors: congenital anomalies of the kidney and urinary tract,
             constipation, bladder dysfunction, myelomeningocele, sexual activity in girls

          -  ≥1 episode of urinary tract infection in the last 6 months

        Exclusion Criteria:

          -  intake of probiotic preparations for ≥1 month in the last 3 months

          -  known allergy to the study products

          -  immunosuppression therapy

          -  disease with immune deficiency

          -  children with other coexisting infection, e.g. meningitis, sepsis, pneumonia, otitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malgorzata Panczyk-Tomaszewska, Assistant Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Daniel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanna Szymanik-Grzelak, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Daniel, MD</last_name>
    <phone>696477117</phone>
    <phone_ext>0048</phone_ext>
    <email>maria.daniel@wum.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanna Szymanik-Grzelak, PhD</last_name>
    <phone>223179656</phone>
    <phone_ext>0048</phone_ext>
    <email>h.szymanik@interia.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital for The Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Tewary K, Narchi H. Recurrent urinary tract infections in children: Preventive interventions other than prophylactic antibiotics. World J Methodol. 2015 Jun 26;5(2):13-9. doi: 10.5662/wjm.v5.i2.13. eCollection 2015 Jun 26.</citation>
    <PMID>26140267</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015 Dec 23;(12):CD008772. doi: 10.1002/14651858.CD008772.pub2. Review.</citation>
    <PMID>26695595</PMID>
  </results_reference>
  <results_reference>
    <citation>Hosseini M, Yousefifard M, Ataei N, Oraii A, Mirzay Razaz J, Izadi A. The efficacy of probiotics in prevention of urinary tract infection in children: A systematic review and meta-analysis. J Pediatr Urol. 2017 Dec;13(6):581-591. doi: 10.1016/j.jpurol.2017.08.018. Epub 2017 Oct 9. Review.</citation>
    <PMID>29102297</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary Tract Infection</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

